Bachewar 2009.

Methods	Design: randomized controlled trial Generation of allocation sequence: computer generated Allocation concealment: unclear Blinding: none Inclusion of randomized participants in the analysis: 78% (23/103 lost to follow up)
Participants	Number: 103 enrolled (aged over 12; 63 males, 40 females) Inclusion criteria: clinically diagnosed scabies Exclusion criteria: pregnancy; lactation; women of child bearing age; abnormal liver or kidney function; thyroid disease; cardiac disorders; nervous system disorders; psychiatric illness; diabetes mellitus; hypertension; chronic infectious disease; any concurrent medication; consuming tobacco, alcohol, or any substance of abuse; any other associated skin disease which could alter the picture of scabies; known/suspected immunocompromised individuals; having scabies with atypical presentations including crusted scabies and scabies incognito; any antiscabetic treatment in the preceding week; noncompliant participants.
Interventions	1. 25% benzyl benzoate lotion applied to whole body below neck and left overnight, on 2 consecutive nights (35 participants) 2. 5% permethrin cream applied to whole body below neck and left overnight (34 participants) 3. Oral ivermectin 200 µg/kg bodyweight single dose (34 participants) Not included in this review: 4. Second topical application of 25% benzyl benzoate lotion at 1 week for treatment failures in intervention group 1 (benzyl benzoate) 5. Second topical application of 5% permethrin cream at 1 week for treatment failures in intervention group 2 (permethrin) 6. Second dose of oral ivermectin at 1 week for treatment failures in intervention group 3 (ivermectin)
Outcomes	1. Number of participants cured at 1 week (defined as absence of new papules, vesicles or classical burrows) 2. Adverse events Not included in this review: 3. Number of participants cured at 2 weeks (defined as absence of new papules, vesicles or classical burrows) 4. Itching recorded on visual analogue scale
Notes	Location: Nagpur, India Date: March to July 2007 All family members and close contacts treated at same time as the participant with 25% benzyl benzoate lotion